Medigus Announces Corporate Rebranding Changes Name to Xylo Technologies Ltd. to Reflect Core Values of its Business
2024年4月10日 - 5:03AM
Medigus Ltd. (NASDAQ: MDGS) (“Medigus” or the “Company”), a
technology-based company engaged in advanced innovative
technologies, announced today a corporate rebranding to reflect
current focus in innovation technologies. At the heart of this
rebranding is a change of the Company’s name to Xylo Technologies
Ltd. to embody its corporate vision and core values.
The rebranding includes a new name and an update
to the Company’s corporate logo, as well as a new website.
In addition, the Company’s Nasdaq trading
symbols will change to XYLO. The Company will begin trading on the
Nasdaq Capital Market (“Nasdaq”) under its new name “Xylo
Technologies Ltd.” and new trading symbol “XYLO” upon the opening
of the market on April 18, 2024.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technology company focused on innovative growth partnerships,
mainly in advanced medical solutions, digital commerce and electric
vehicle markets. Medigus' affiliations in the medical solutions
arena include ownership in Polyrizon Ltd. The Company’s affiliates
in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd.,
and Eventer Technologies Ltd. In the electric vehicle market,
Charging Robotics Ltd., and Revoltz Ltd., by way of Fuel Doctor
Holdings, Inc. are also part of the Company’s portfolio of
technology solution providers. Medigus is traded on Nasdaq Capital
Market. To learn more about Medigus’ advanced technologies, please
visit http://www.medigus.com/.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. Because such statements deal with
future events and are based on Medigus’ current expectations, they
are subject to various risks and uncertainties, and actual results,
performance or achievements could differ materially from those
described in or implied by the statements in this press
release.
The forward-looking statements contained or
implied in this press release are subject to other risks and
uncertainties, including those discussed in any filings with the
SEC. Except as otherwise required by law, Medigus undertakes no
obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Medigus is not
responsible for the contents of third-party websites.
Company Contact: Tali DinarChief
Financial Officer+972-8-6466-880ir@medigus.com
Investor Relations Contact:Michal
EfratyInvestor Relations,
Israel+972-(0)52-3044404michal@efraty.com
Medigus (NASDAQ:MDGS)
過去 株価チャート
から 6 2024 まで 7 2024
Medigus (NASDAQ:MDGS)
過去 株価チャート
から 7 2023 まで 7 2024